Baxter announces European launch of Numeta G13E 300 ml, the only ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm infants.

Baxter International Inc., a global leader in Parenteral Nutrition therapy, announced the European launch of Numeta G13E 300 ml, the only ready-to-use parenteral (intravenous) nutrition (PN) product available to treat preterm infants (less than 37 weeks gestation age) who are at high risk for infection and malnutrition in the early hours and days of their lives. The announcement was made during the 38th ESPEN (The European Society for Clinical Nutrition and Metabolism) Congress in Copenhagen, Sept. 17-20, with recognition that the first preterm patients have received PN therapy on Numeta G13E in Sweden.

Baxter�s Numeta G13E has Marketing Authorization from the Competent Authorities in 15 Western European countries, including Austria, Belgium, France, Germany, Ireland, Malta Netherlands, Poland, Switzerland, the U.K., and the Nordics where the launch initiated. Baxter plans to continue pursuing regulatory approvals and launching Numeta G13E globally, including in additional European countries and Latin America in 2017.

Baxter offers additional pediatric triple-chamber PN solutions in Europe and select Latin American countries, including Numeta G16E 500mL for term infants and toddlers (term infants through two years of age); and Numeta G19E 1,000mL for children and adolescents (2-18 years of age).

Comment: Numeta G13E was reformulated to meet the current pediatric nutritional guidelines developed by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN).